|RxNews Recap for Wednesday 12-09-09|
|By Mary Davila|
|Thursday, 10 December 2009 00:39|
Biotech investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Stock Quotes box on the right side of the page.
AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, is pleased to announce the appointment of Pierre Lapalme to its Board of Directors.
ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that the Company's Principal Executive Officer, Brian M. Culley, will present to investorsas part of the Lippert/Heilshorn & Associates Life Sciences On-line Forum on December 15, 2009 at 9:30 a.m. Eastern time.
BioMed Realty Trust, Inc. (NYSE:BMR) announced today the expiration and final results of the previously announced cash tender offer by its operating partnership, BioMed Realty, L.P., for any and all of its outstanding 4.50% Exchangeable Senior Notes due 2026 (the "Notes").
Cortex Pharmaceuticals, Inc. (NYSE Amex: COR) announced that it has received notification from the NYSE Amex LLC indicating that, due to the Company’s non-compliance with certain continued listing standards as previously reported, the Exchange intends to delist the Company’s common stock from the NYSE Amex effective as of the close of business on Friday, December 11, 2009.
Elan Corporation, plc (NYSE: ELN) today announced that it will present at the Deutsche Bank Securities Biotech Boston Confab Conference, on Tuesday, December 15, 2009, at 10:30 a.m. Eastern Time and 3:30 p.m. GMT.
Exelixis, Inc. (NASDAQ:EXEL) announced today that George A. Scangos, PhD, the company’s president and chief executive officer, will present at the 28th Annual J.P. Morgan Healthcare Conference at 11:00 a.m. EST / 8:00 a.m. PST on Tuesday January 12, 2010 in San Francisco.
Fero Industries, Inc. (OTCBB: FROI) (the “Company”), is pleased to disclose its growth strategy. FROI’s first acquisition target is Pyro Pharmaceuticals, Inc., a boutique developmental stage pharmaceutical company located in Irvine, CA.
Forest Laboratories, Inc. (NYSE: FRX) announced today Peter J. Zimetbaum, M.D., has been named to the Board of Directors. Dr. Zimetbaum was elected to serve unanimously by the Board at the Company's last regularly scheduled Board of Directors meeting held in New York. With Dr. Zimetbaum’s appointment Forest’s Board of Directors is increased from eight to nine members.
Genzyme Corporation (NASDAQ: GENZ) announced today that its genetic testing laboratory located in Phoenix, Arizona, has obtained the CAP 15189SM Accreditation to the International Standards Organization 15189:2007 Standard for laboratories from the College of American Pathologists.
Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) today reported results for the quarter ended October 31, 2009.
Lifeline Skin Care, Inc, a wholly owned subsidiary of International Stem Cell Corporation (OTCBB:ISCO), announced today that it has retained the services of a highly experienced expert in the skin care industry, Raulee Marcus, to help design a marketing program for its newly created line of skin care products based on ISCO’s proprietary Parthenogenic Stem Cells.
Mach One Corporation (OTCBB: MNCN), a rapidly growing, innovative, global wellness solutions company, today announced January 15, 2010 as the new deadline to complete the acquisition of White Hat Brands, LLC, producers of a variety of all natural, multi-vitamin-fortified juice beverages for children under the brand name Dog On It!™.
Medidata Solutions (NASDAQ: MDSO), a leading global provider of hosted clinical development solutions, today announced the pricing of 5,500,000 shares of its common stock at $15.00 per share in a public offering by a number of its stockholders.
Repligen Corporation (Nasdaq: RGEN) reported today top-line results from a Phase 3 clinical trial to evaluate the safety and efficacy of RG1068, synthetic human secretin, to improve magnetic resonance imaging (MRI) of the pancreas in patients with a history of pancreatitis.
Regenerx Biopharmaceuticals, Inc., (NYSE Amex:RGN) announced today that it has completed and analyzed the safety data from its double-blind, placebo controlled Phase I clinical trial evaluating the systemic administration of RGN-352.
Unigene Laboratories, Inc. (OTCBB:UGNE) has announced a restructuring plan that includes a reduction in workforce to improve operational efficiencies and to better match resources with market demand and the Company’s strategic objectives.
Watson Pharmaceuticals, Inc. (NYSE:WPI) today announced that the results of an open-label extension of two Phase 3 studies, published in the December issue of the peer-reviewed journal Urology, demonstrate long-term safety and tolerability of RAPAFLO® (silodosin) for up to 52 weeks of treatment.